Juno Therapeutics, Inc. (NASDAQ:JUNO) EVP Robert Azelby sold 12,850 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $44.95, for a total transaction of $577,607.50. Following the sale, the executive vice president now directly owns 37,439 shares of the company’s stock, valued at approximately $1,682,883.05. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Robert Azelby also recently made the following trade(s):

  • On Tuesday, August 29th, Robert Azelby sold 12,869 shares of Juno Therapeutics stock. The stock was sold at an average price of $39.95, for a total transaction of $514,116.55.

Juno Therapeutics, Inc. (JUNO) traded down 1.65% during mid-day trading on Thursday, reaching $44.57. 4,713,333 shares of the company traded hands. Juno Therapeutics, Inc. has a 12-month low of $17.52 and a 12-month high of $47.00. The company’s 50-day moving average is $33.60 and its 200-day moving average is $26.98. The stock’s market capitalization is $4.68 billion.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.24). The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. Juno Therapeutics’s revenue for the quarter was down 22.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.64) EPS. Equities analysts predict that Juno Therapeutics, Inc. will post ($3.12) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/09/14/juno-therapeutics-inc-juno-evp-sells-577607-50-in-stock.html.

Several brokerages have recently commented on JUNO. Vetr raised shares of Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price objective for the company in a research report on Monday, August 14th. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Morgan Stanley raised their price objective on shares of Juno Therapeutics from $26.00 to $27.00 and gave the stock an “equal weight” rating in a research report on Monday, August 7th. Wedbush reaffirmed a “neutral” rating and set a $24.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, June 6th. Finally, BidaskClub downgraded shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, June 10th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company. Juno Therapeutics has an average rating of “Hold” and an average target price of $34.88.

Institutional investors and hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company raised its holdings in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 228 shares in the last quarter. Pacad Investment Ltd. bought a new position in Juno Therapeutics in the second quarter worth $105,000. QS Investors LLC bought a new position in Juno Therapeutics in the second quarter worth $135,000. Great West Life Assurance Co. Can raised its holdings in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 3,800 shares in the last quarter. Finally, Nisa Investment Advisors LLC bought a new position in Juno Therapeutics in the first quarter worth $200,000. Institutional investors and hedge funds own 70.76% of the company’s stock.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.